ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer

British Journal of Cancer

Volumn 112, Issue 4, 2015, Pages 704-713

  Watanabe, T ^a,b   Ueno, H ^c   Watabe, Y ^a   Hiraoka, N ^a   Morizane, C ^c   Itami, J ^a   Okusaka, T ^c   Miura, N ^a   Kakizaki, T ^a   Kakuya, T ^a   Kamita, M ^a   Tsuchida, A ^b   Nagakawa, Y ^b   Wilber, H ^d   Yamada, T ^a   Honda, K ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d Abnova Company   (Taiwan)

Author keywords

chemoradiotherapy; chemotherapy; copy number increase of ACTN4; locally advanced pancreatic cancer; predictive biomarker

Indexed keywords

ALPHA ACTININ 4; BIOLOGICAL MARKER; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ACTININ; ACTN4 PROTEIN, HUMAN; PHARMACOLOGICAL BIOMARKER; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; LOCALLY ADVANCED PANCREATIC CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR BIOPSY; ADENOCARCINOMA; AGED; DISEASE COURSE; GENETICS; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ACTININ; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, PHARMACOLOGICAL; BIOMARKERS, TUMOR; CHEMORADIOTHERAPY; DISEASE PROGRESSION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84923640367     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.623     Document Type: Article

References (29)

1. Berger AC, Garcia Jr. M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson 3rd AB, MacDonald J, Willett CG. (2008). Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 26(36): 5918-5922
2. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L. (2008). Phase III trial comparing intensive induction chemoradiotherapy (60Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19(9): 1592-1599
3. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M. (2002). Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94(4): 902-910
4. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. (2011). Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29(22): 3037-3043
5. Hayashida Y, Honda K, Idogawa M, Ino Y, Ono M, Tsuchida A, Aoki T, Hirohashi S, Yamada T. (2005). E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res 65(19): 8836-8845
6. Honda K, Okusaka T, Felix K, Nakamori S, Sata N, Nagai H, Ioka T, Tsuchida A, Shimahara T, Shimahara M, Yasunami Y, Kuwabara H, Sakuma T, Otsuka Y, Ota N, Shitashige M, Kosuge T, Buchler MW, Yamada T. (2012). Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation. PLoS One 7(10): e46908
7. Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H, Yamada Y, Chiba H, Hirohashi S. (1998). Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol 140(6): 1383-1393
8. Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, Ino Y, Ono M, Hirohashi S. (2005). Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 128(1): 51-62
9. Huguet F, Andre T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, De Gramont A, Louvet C. (2007). Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25(3): 326-331
10. Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse J, Ishii H, Kawashima M, Kagami Y, Ikeda H. (2007). A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer 96(11): 1650-1655
11. Johung K, Saif MW, Chang BW. (2012). Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys 82(2): 508-518
12. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA. (2013). Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 20(8): 2787-2795
13. Kikuchi S, Honda K, Handa Y, Kato H, Yamashita K, Umaki T, Shitashige M, Ono M, Tsuchida A, Aoki T, Hirohashi S, Yamada T. (2007). Serum albumin-associated peptides of patients with uterine endometrial cancer. Cancer Sci 98(6): 822-829
14. Kikuchi S, Honda K, Tsuda H, Hiraoka N, Imoto I, Kosuge T, Umaki T, Onozato K, Shitashige M, Yamaguchi U, Ono M, Tsuchida A, Aoki T, Inazawa J, Hirohashi S, Yamada T. (2008). Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res 14(17): 5348-5356
15. Loehrer Sr. PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson 3rd AB. (2011). Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29(31): 4105-4112
16. Mayahara H, Ito Y, Morizane C, Ueno H, Okusaka T, Kondo S, Murakami N, Morota M, Sumi M, Itami J. (2012). Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. BMC Cancer 12: 609
17. Mian OY, Ram AN, Tuli R, Herman JM. (2014). Management options in locally advanced pancreatic cancer. Curr Oncol Rep 16(6): 388
18. Miyanaga A, Honda K, Tsuta K, Masuda M, Yamaguchi U, Fujii G, Miyamoto A, Shinagawa S, Miura N, Tsuda H, Sakuma T, Asamura H, Gemma A, Yamada T. (2013). Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours. Ann Oncol 24(1): 84-90
19. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. National Cancer Institute of Canada Clinical Trials G. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15): 1960-1966
20. Noro R, Honda K, Tsuta K, Ishii G, Maeshima AM, Miura N, Furuta K, Shibata T, Tsuda H, Ochiai A, Sakuma T, Nishijima N, Gemma A, Asamura H, Nagai K, Yamada T. (2013). Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. Ann Oncol 24(10): 2594-2600
21. Otey CA, Carpen O. (2004). Alpha-actinin revisited: a fresh look at an old player. Cell Motil Cytoskeleton 58(2): 104-111
22. Pawlik TM, Laheru D, Hruban RH, Coleman J, Wolfgang CL, Campbell K, Ali S, Fishman EK, Schulick RD, Herman JM. Johns Hopkins Multidisciplinary Pancreas Clinic T. (2008). Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol 15(8): 2081-2088
23. Savir G, Huber KE, Saif MW. (2013). Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. JOP 14(4): 337-339
24. Watabe Y, Mori T, Yoshimoto S, Nomura T, Shibahara T, Yamada T, Honda K. (2014). Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma. Cancer Med 3(3): 613-622
25. Welsch T, Keleg S, Bergmann F, Bauer S, Hinz U, Schmidt J. (2009). Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma. Pancreas 38(8): 968-976
26. Yamamoto S, Tsuda H, Honda K, Kita T, Takano M, Tamai S, Inazawa J, Yamada T, Matsubara O. (2007). Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod Pathol 20(12): 1278-1285
27. Yamamoto S, Tsuda H, Honda K, Onozato K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T, Matsubara O. (2009). Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol 22(4): 499-507
28. Yamamoto S, Tsuda H, Honda K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T, Matsubara O. (2012). ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. Histopathology 60(7): 1073-1083
29. Yang GY, Malik NK, Chandrasekhar R, Ma WW, Flaherty L, Iyer R, Kuvshinoff B, Gibbs J, Wilding G, Warren G, May KS. (2013). Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol 4(4): 361-369